A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE II MULTI-CENTER, PARALLEL-GROUP, RANDOMIZED, DOUBLE BLIND, PROOF-OF-CONCEPT, ADAPTIVE STUDY INVESTIGATING THE SAFETY AND EFFICACY OF THR-184 ADMINISTERED VIA INTRAVENOUS INFUSION IN PATIENTS AT INCREASED RISK OF DEVELOPING CARDIAC SURGERY ASSOCIATED-ACUTE KIDNEY INJURY (CSA-AKI)

Intervention/treatment:
THR-184
Medical condition:
RENAL FAILURE
Protocol code:
A-003
Control number:
163227
Status:
Closed
Approved:
April 12, 2013
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT01830920
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 85 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Jerome Rossert, MD, PhD, Chief Scientific Officer
Organization
Thrasos Therapeutics, Inc.
Sponsor
THRASOS INNOVATION INC

Locations

Alberta

Foothills Medical Centre
Calgary, Alberta, T2N 2T9

New Brunswick

St-John Regional Hospital Facility
Saint John, New Brunswick, E2L4L2

Ontario

Hamilton Health Sciences Corporation
Hamilton, Ontario, L8L 2X2
St. Michael's Hospital
Toronto, Ontario, M5B 1W8
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7

Quebec

Centre hospitalier de l'université de Montréal(CHUM)- Hôtel-Dieu
Montreal, Quebec, H2W 1T8
Institut de Cardiologie de Montréal
Montreal, Quebec, H1T 1C8
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Quebec, G1V 4G5
MUHC - Royal Victoria Hospital
Montreal, Quebec, H3A 1A1
Sacre Cœur Hospital
Montreal, Quebec, H4J 1C5

Results

See the results from the trial NCT01830920. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?